POM-V Prescription Required Companion Animal

Trovex 1 mg/ml Suspension for Injection for Cattle, Horses, Pigs, Cats and Dogs

Active ingredient: Dexamethasone Isonicotinate

Form

Injection

Species

Cats Cattle Dogs Horses Pigs

Manufacturer

Emdoka

VMD MA No.

34534/4008

What it's used for

Cattle: Treatment of ketosis (acetonaemia). AN: 03961/2024 & 03963/2024

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Dexamethasone Isonicotinate

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Trovex 1 mg/ml Suspension for Injection for Cattle, Horses, Pigs, Cats and Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Cattle:
Treatment of ketosis (acetonaemia).
AN: 03961/2024 & 03963/2024

Cattle, calves, horses and foals: 0.02 mg of dexamethasone isonicotinate/kg body
weight (equivalent to 0.016 mg of dexamethasone/kg) corresponding to 2 ml/100 kg
bodyweight
Pigs: 0.02 mg of dexamethasone isonicotinate/kg body weight (equivalent to 0.016
mg of dexamethasone/kg) corresponding to 2 ml/100 kg bodyweight
Piglets: 0.1 mg of dexamethasone isonicotinate/kg body weight (equivalent to 0.08
mg of dexamethasone/kg) corresponding to 1 ml/10 kg bodyweight
The maximal volume to be administered per injection site is 10 ml in cattle and
horses and 3 ml in pigs.
Dogs and cats
Intramuscular or subcutaneous administration.
Dogs and cats: 0.1 mg of dexamethasone isonicotinate/kg body weight (equivalent to
0.08 mg of dexamethasone/kg) corresponding to 1 ml/10 kg bodyweight
The therapeutic effect of the product lasts for approximately 4 days. In horses, cats
and dogs, where longer term treatment is necessary, an appropriate corticosteroid
preparation should be used.
Shake well before use. An appropriately graduated syringe must be used to allow
accurate administration of the required dose volume. This is particularly important
when injecting small volumes.
Do not broach the vial more than 25 times.

Except in emergency situations, do not use in animals suffering from diabetes
mellitus, renal insufficiency, cardiac insufficiency, hyperadrenocorticism, or
osteoporosis.
Do not use in viral infections during the viraemic stage or in cases of systemic
mycotic infections.
Do not use in animals suffering from gastrointestinal or corneal ulcers, or
demodicosis.
Do not use in animals with known cases of hypersensitivity to the active substance,
to corticosteroids and to any other ingredient of the product.
See also section 3.7.
Do not use for the treatment of laminitis in horses, where there is the possibility that
such treatment could worsen the condition.

Cattle:
Undetermined frequency
(cannot be estimated from the
available data):
Cushing's disease
Polyuria, polydipsia, polyphagia
Hypokalaemia
Cutaneous calcinosis, skin atrophy
Delayed healing, exacerbation of existing
infections
Gastric ulceration
Enlarged liver
Changes in blood biochemical and
haematological parameters
Hyperglycaemia
Acute pancreatitis
Laminitis
Milk drop
Anaphylactic reactions
1
Significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g.
redistribution of body fat, muscle weakness and wastage and osteoporosis may
result. During therapy effective doses suppress the Hypothalamo-Pituitary-Adrenal
axis. Following cessation of treatment, symptoms of adrenal insufficiency extending
to adrenocortical atrophy can arise and this may render the animal unable to deal
adequately with stressful situations.
When administered systemically, particularly during the early stages of therapy.
After long-term use
In the presence of bacterial infection, anti-bacterial drug cover is usually required
when steroids are used. In the presence of viral infections, steroids may worsen or
hasten the progress of disease.
May also be exacerbated by steroids in patients given non-steroidal anti-
inflammatory drugs and in corticosteroid-treated animals with spinal cord trauma.
With increased serum hepatic enzymes.
Transient.
Which may be fatal.
AN: 03961/2024 & 03963/2024
Horses, pigs:
Undetermined frequency
(cannot be estimated from the
available data):
Cushing's disease
Polyuria, polydipsia, polyphagia
Hypokalaemia
Cutaneous calcinosis, skin atrophy
Delayed healing, exacerbation of existing
infections
Gastric ulceration
Enlarged liver
Changes in blood biochemical and
haematological parameters
Hyperglycaemia
Acute pancreatitis
Laminitis
Anaphylactic reactions
1
Significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g.
redistribution of body fat, muscle weakness and wastage and osteoporosis may
result. During therapy effective doses suppress the Hypothalamo-Pituitary-Adrenal
axis. Following cessation of treatment, symptoms of adrenal insufficiency extending
to adrenocortical atrophy can arise and this may render the animal unable to deal
adequately with stressful situations.
When administered systemically, particularly during the early stages of therapy.
After long-term use
In the presence of bacterial infection, anti-bacterial drug cover is usually required
when steroids are used. In the presence of viral infections, steroids may worsen or
hasten the progress of disease.
May also be exacerbated by steroids in patients given non-steroidal anti-
inflammatory drugs and in corticosteroid-treated animals with spinal cord trauma.
With increased serum hepatic enzymes.
Transient.
Which may be fatal.
Dogs, cats:
Undetermined frequency
(cannot be estimated from the
available data):
Cushing's disease
Polyuria, polydipsia, polyphagia
Hypokalaemia
Cutaneous calcinosis, skin atrophy
Delayed healing, exacerbation of existing
infections
Gastric ulceration
Enlarged liver
Behavioural disorder
Changes in blood biochemical and
haematological parameters
Hyperglycaemia
Acute pancreatitis
Anaphylactic reactions
1
Significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g.
redistribution of body fat, muscle weakness and wastage and osteoporosis may
result. During therapy effective doses suppress the Hypothalamo-Pituitary-Adrenal
AN: 03961/2024 & 03963/2024
axis. Following cessation of treatment, symptoms of adrenal insufficiency extending
to adrenocortical atrophy can arise and this may render the animal unable to deal
adequately with stressful situations.
When administered systemically, particularly during the early stages of therapy.
After long-term use
In the presence of bacterial infection, anti-bacterial drug cover is usually required
when steroids are used. In the presence of viral infections, steroids may worsen or
hasten the progress of disease.
May also be exacerbated by steroids in patients given non-steroidal anti-
inflammatory drugs and in corticosteroid-treated animals with spinal cord trauma.
With increased serum hepatic enzymes.
Occasional depression in cats and dogs, aggressiveness in dogs.
Transient.
Which may be fatal.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Special precautions for safe use in the target species:
During a course of treatment the situation should be reviewed frequently by close
veterinary supervision.
Care should be taken not to overdose Channel Island breeds of cattle.
Use of corticosteroids in horses has been reported to induce laminitis. Therefore
horses treated with such preparations should be monitored frequently during the
treatment period.
Because of the pharmacological properties of the active ingredient, special care
should be taken when the product is used in animals with a weakened immune
system.
Except in cases of ketosis, corticosteroid administration is to induce an improvement
in clinical signs rather than a cure.
The underlying disease should be further investigated.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
This veterinary medicinal product contains dexamethasone and
parahydroxybenzoates (parabens), which can cause allergic reactions in some
people.
People with known hypersensitivity to dexamethasone or to any of the excipients
should avoid contact with the veterinary medicinal product.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Dexamethasone may affect fertility or the unborn child. Pregnant women should not
handle this veterinary medicinal product.
AN: 03961/2024 & 03963/2024
This veterinary medicinal product is a skin and eye irritant. Avoid contact with skin
and eyes. In the event of accidental eye or skin contact, wash/irrigate the area with
clean running water. Seek medical attention if irritation persists.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.

Dexamethasone should not be given together with other anti-inflammatory
substances. Concurrent use with non-steroidal anti-inflammatory drugs may
exacerbate gastrointestinal tract ulceration.
Because corticosteroids can reduce the immune response to vaccination,
dexamethasone should not be used in combination with vaccines or within two weeks
after vaccination.
Administration of dexamethasone may induce hypokalaemia and hence increase the
risk of toxicity from cardiac glycosides.
The risk of hypokalaemia may be increased if dexamethasone is administered
together with potassium depleting diuretics.
Concurrent use with anticholinesterase may lead to increased muscle weakness in
patients with myasthenia gravis.
Glucocorticoids antagonise the effects of insulin.
Concurrent use with phenobarbital, phenytoin and rifampicin can reduce the effects
of dexamethasone.
Amphotericin B administered concomitantly with glucocorticoids may cause
hypokalemia.
Glucocorticoids may also inhibit the hepatic metabolism of cyclophosphamide;
dosage adjustments may be required.
AN: 03961/2024 & 03963/2024
Concomitant administration of glucocorticoids and cyclosporine may increase the
blood levels of each, by mutually inhibiting the hepatic metabolism of each other; the
clinical significance of this interaction is not clear.
Dexamethasone may decrease diazepam levels.
Ephedrine may reduce dexamethasone blood levels and interfere with
dexamethasone suppression tests.
Ketoconazole and other azole antifungals may decrease the metabolism of
glucocorticoids and increase dexamethasone blood levels; ketoconazole may induce
adrenal insufficiency when glucocorticoids are withdrawn by inhibiting adrenal
corticosteroid synthesis.
Macrolide antibiotics (erythromycin, clarithromycin) may decrease the metabolism of
glucocorticoids and increase dexamethasone blood levels.
Mitotane may alter the metabolism of steroids; higher than usual doses of steroids
may be necessary to treat mitotane-induced adrenal insufficiency.

Do not refrigerate or freeze.
Keep the vial in the outer carton in order to protect from light.

Cattle:
Meat and offal: 55 days
Milk: 60 hours
Horses:
Meat and offal: 63 days
Not authorised for use in horses producing milk for human consumption.
Pigs:
Meat and offal: 55 days

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.